Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
23 Cards in this Set
- Front
- Back
|
nifedipine
|
Procardia
Ca Blocker on vascular smooth muscle (subclass: dihydropyridines) Reduces blood pressure (peripheral resistance) increasing blood flow in coronary vessels. |
|
|
verapamil
|
Calan
Ca Blocker on vascular smooth muscle cardiac muscle (1° effect) (subclass: diphenylalkylamines) Reduces blood pressure (peripheral resistance) increasing blood flow in coronary vessels. Effects: negative chronotropic effect negative dromotopic effect negative inotropic effect |
|
|
diltiazem
|
Cardizem
Ca Blocker on vascular smooth muscle & cardiac muscle (subclass: benzothiazepines) Reduces blood pressure (peripheral resistance) increasing blood flow in coronary vessels. |
|
|
classes of drugs for treating angina
|
organic nitrates and nitrites
beta adrenergic blockers ca channel blockers |
|
|
MOA
organic nitrates and nitrites |
vessel dilation and inhibits platelet aggregation (via interaction with sulfhydryl groups producing nitric oxide and s-nitrosothiol)
increases cyclic GMP = decreasing Ca = vessel dilation & reduced aggregation & adhesion |
|
|
Classification
organic nitrates and nitrites |
rapid onset & short duration
longer onset & longer duration |
|
|
nitroglyglycerin
|
organic nitrates and nitrites
used for acute anginal attack rapid onset & short duration ADMIN: sublingual (pill), IV, spray = all bypass first metabolism MOA: vessel dilation and inhibits platelet aggregation (via interaction with sulfhydryl groups producing nitric oxide and s-nitrosothiol) increases cyclic GMP = decreasing Ca = vessel dilation & reduced aggregation & adhesion |
|
|
isosorbide dinitrate
|
organic nitrates and nitrites
used for acute anginal attack rapid onset & short duration ADMIN: sublingual (pill) MOA: vessel dilation and inhibits platelet aggregation (via interaction with sulfhydryl groups producing nitric oxide and s-nitrosothiol) increases cyclic GMP = decreasing Ca = vessel dilation & reduced aggregation & adhesion |
|
|
nitroglycerin
|
organic nitrates and nitrites
long onset & longer duration ADMIN:extended release tablet, transdermal ointment/patch MOA: vessel dilation and inhibits platelet aggregation (via interaction with sulfhydryl groups producing nitric oxide and s-nitrosothiol) increases cyclic GMP = decreasing Ca = vessel dilation & reduced aggregation & adhesion |
|
|
isosobide dinitrate
|
long onset & longer duration
ADMIN: oral tablet MOA: vessel dilation and inhibits platelet aggregation (via interaction with sulfhydryl groups producing nitric oxide and s-nitrosothiol) increases cyclic GMP = decreasing Ca = vessel dilation & reduced aggregation & adhesion |
|
|
isosorbide-5-mononitrate (imdur)
|
long onset & longer duration
ADMIN: oral tablet 1x day MOA: vessel dilation and inhibits platelet aggregation (via interaction with sulfhydryl groups producing nitric oxide and s-nitrosothiol) increases cyclic GMP = decreasing Ca = vessel dilation & reduced aggregation & adhesion |
|
|
Adverse Rxn
organic nitrates & nitrites |
headaches
flushing orthostatic hypotension GI tract nausea & vomiting |
|
|
MOA
beta adrenergic blocker |
blocking beta 1 inhibits activation of adenyl cyclase reducing Ca
fixed & unstable angina, MI Effect - chronotropic effect - dromotropic effect - inotropic effect |
|
|
Classification
beta adrenergic blocker |
non cardio-selective beta blocker (block b1 & b2)
cardioselective beta blocker (block b1) beta blocker w/ intrinsic sym-mimetic activity (partial agonost/antagonist) |
|
|
propranolol
|
non cardio-selective beta blocker (block b1 & b2)
prototype MOA: blocking beta 1 inhibits activation of adenyl cyclase reducing Ca |
|
|
atenolol
|
cardioselective beta blocker (block b1)
MOA: blocking beta 1 inhibits activation of adenyl cyclase reducing Ca |
|
|
metoprolol
|
cardioselective beta blocker (block b1)
MOA: blocking beta 1 inhibits activation of adenyl cyclase reducing Ca |
|
|
pindolol
|
beta blocker w/ intrinsic sym-mimetic activity (partial agonost/antagonist)
MOA: blocking beta 1 inhibits activation of adenyl cyclase reducing Ca |
|
|
acebutolol
|
beta blocker w/ intrinsic sym-mimetic activity (partial agonost/antagonist)
MOA: blocking beta 1 inhibits activation of adenyl cyclase reducing Ca |
|
|
negative chronotropic effect
|
decrease heart rate
|
|
|
negative dromotropic effect
|
decrease heart conduction rate
|
|
|
negative inotropic effect
|
decrease force of contraction
|
|
|
Adverse Rxn
beta-adrenergic blocker |
CNS sedation
bronchospasm worsening claudication hypoglycemia withdrawal congestive heart failure |
